MedTrace Logo

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

NCT06237049 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 644

Last updated 2025-09-30

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.

Conditions

Interventions

BIOLOGICAL

BNT162b2 (Omi XBB.1.5)/RIV

Combination of BNT162b2 (Omi XBB.1.5) and RIV

BIOLOGICAL

BNT162b2 (Omi XBB.1.5)

Licensed COVID-19 vaccine

BIOLOGICAL

RIV

Licensed recombinant influenza vaccine

OTHER

Normal saline placebo

Normal saline (solution for injection)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-09-13
Completion
2024-09-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237049 on ClinicalTrials.gov